TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG

Trevor Leong; B Mark Smithers; Karin Haustermans; Michael Michael; Val Gebski; Danielle Miller; John Zalcberg; Alex Boussioutas; Michael Findlay; Rachel L O'Connell; Jaclyn Verghis; David Willis; Tomas Kron; Melissa Crain; William K Murray; Florian Lordick; Carol Swallow; Gail Darling; John Simes; Rebecca Wong

Journal article

TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG

Trevor Leong, B Mark Smithers, Karin Haustermans, Michael Michael, Val Gebski, Danielle Miller, John Zalcberg, Alex Boussioutas, Michael Findlay, Rachel L O'Connell, Jaclyn Verghis, David Willis, Tomas Kron, Melissa Crain, William K Murray, Florian Lordick, Carol Swallow, Gail Darling, John Simes, Rebecca Wong

Annals of Surgical Oncology | SPRINGER | Published : 2017

DOI: 10.1245/s10434-017-5830-6

University of Melbourne Researchers

John Zalcberg Author Medicine - St Vincent's Hospital

William Murray Author Clinical Pathology

Michael Michael Author Medicine - St Vincent's Hospital

Trevor Leong Author Clinical Pathology

Tomas Kron Author The Sir Peter MacCallum Department of Oncology

Related Projects (1)

Topgear: Trial Of Preoperative Therapy For Gastric And Esophagogastric Junction Adenocarcinoma. A Randomised Phase Til Trial Of Preoperative Chemoradiotherapy Versus Preoperative Chemotherapy For Resectable Gastric Cancer

While surgery to remove gastric (stomach) cancer has been traditionally accepted as the only way to potentially cure the disease, there have..

Grants

Awarded by National Health and Medical Research Council

Awarded by Canadian Institutes of Health Research (CIHR)

Awarded by Canadian Cancer Society Research Institute (CCSRI)

Awarded by Health Research Council of New Zealand (HRC)

Awarded by Cancer Australia Priority-Driven Collaborative Research Scheme

Funding Acknowledgements

This work was supported by grants from the National Health and Medical Research Council (1046425), Canadian Institutes of Health Research (CIHR) Grant No. 119445, the Canadian Cancer Society Research Institute (CCSRI) Grant No. 021039, the Health Research Council of New Zealand (HRC) International Investment Opportunities Fund (contract number 09/624), the EORTC Cancer Research Fund, and the Cancer Australia Priority-Driven Collaborative Research Scheme (Project ID 570996). Rhana Pike, from the National Health and Medical Research Council (NHMRC) Clinical Trials Centre, assisted with the manuscript.